Grace Therapeutics, Inc. (GRCE) Stock Analysis & Investment Frameworks
Grace Therapeutics, Inc. (GRCE) stock analysis on Invetso. Review Grace Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Grace Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Grace Therapeutics, Inc. Key Financial Metrics
- Market Cap: $29.46M
- Revenue: $N/A
- ROE: -35.78%
- ROIC: -48.75%
- Dividend Yield: N/A
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Grace Therapeutics, Inc. Investment Frameworks
Invetso analyzes Grace Therapeutics, Inc. (GRCE) across the following frameworks:
- Grace Therapeutics, Inc. 10Y Growth Potential
- Grace Therapeutics, Inc. Scenario Analysis
- Grace Therapeutics, Inc. Risks & Opportunities
- Grace Therapeutics, Inc. Economic Moat
- Grace Therapeutics, Inc. Business Model
- Grace Therapeutics, Inc. Management
- Grace Therapeutics, Inc. SWOT Analysis
- Grace Therapeutics, Inc. Porter's 5 Forces
- Grace Therapeutics, Inc. PESTLE Analysis
- Grace Therapeutics, Inc. ESG Analysis